Abbott, Elan Drop Tricor IP Suits Against Biovail

Law360, New York (April 4, 2011, 4:35 PM EDT) -- Abbott Laboratories and Elan Corp. PLC continued Thursday to wrap up a campaign to block generic versions of the cholesterol drug Tricor, resolving lawsuits against Biovail Corp., which is now owned by Valeant Pharmaceuticals International Inc.

Judge Garrett E. Brown Jr. of the U.S. District Court for the District of New Jersey dismissed Abbott’s infringement suit against Biovail, and signed off on an identical stipulation resolving Elan’s suit over three other Tricor patents.

Abbott and Elan each agreed to dismiss their respective suits against Biovail, with...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.